Highest-materiality recent filing
Assertio completes Zydus merger at $23.50/share; notes conversion set at $382.58 per $1,000
Merger completed June 16; shareholders receive $23.50 per share cash; stock delisted from Nasdaq.
Assertio to be acquired by Zydus Worldwide for $23.50 per share in cash
Zydus Worldwide DMCC will acquire Assertio via tender offer at $23.50/share cash, followed by a merger.
Assertio to be acquired by Zydus for $23.50/share cash; terminates prior Garda deal
All-cash tender offer of $23.50/share (~$166.4M total) by Zydus subsidiary.
Assertio and Garda delay tender offer launch to May 14, 2026
Mutual agreement to extend deadline to commence tender offer for all outstanding shares to May 14, 2026.
Assertio shareholders approve 400,000-share increase in 2014 Omnibus Incentive Plan
Shareholders approved amendment to 2014 Omnibus Incentive Plan to increase available shares by 400,000 (total 2,271,167).
Assertio and Garda postpone tender offer commencement to May 8, 2026
Tender offer to acquire all outstanding ASRT shares for $21.80/share ($153.2M total) postponed from May 4 to May 8.
Assertio increases acquisition price to $21.80/share all cash; Garda's revised offer up 21.1%
Offer price $21.80/share in cash, no CVR, up from $18 plus CVR (21.1% premium to original offer).
Assertio-Garda extend tender offer deadline to May 4, 2026; $125.1M deal
Mutual agreement extends tender offer commencement deadline to May 4, 2026.
Assertio: Garda to launch tender offer April 29 at $18.00/share ($125M cash)
Garda intends to commence tender offer on April 29, 2026 to purchase all outstanding Assertio shares.
Products sold: INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR, OTREXUP; deal closed April 8, 2026.
Assertio to be acquired by Garda Therapeutics in $18.00/share cash tender offer plus CVRs
Acquisition by Garda Therapeutics at $18.00/share cash plus one CVR per share; tender offer to commence within 10 business days.
Assertio to be acquired by Garda for $18/share plus CVR; sells assets to Cosette for $35M
Garda Therapeutics to acquire Assertio via cash tender offer at $18.00 per share plus one CVR per share.
Assertio reports Q4 adjusted EBITDA loss of $4.1M; Rolvedon sales drop to $0.4M from $15.4M
Rolvedon Q4 net sales $0.4M vs $15.4M YoY; sell-in in Q3 2025 covered two quarters of demand, sales under new label expected Q2 2026.
Assertio regains Nasdaq minimum bid price compliance; matter closed
Nasdaq notified Assertio on Jan 12, 2026 of compliance with minimum bid price rule 5550(a)(2).
Assertio Holdings to effect 1:15 reverse stock split effective Dec 26, 2025
Reverse split at ratio 1:15 effective 12:01 a.m. ET on Dec 26, 2025.
Former CEO Brendan O'Grady resigns from Assertio board effective Nov 17, 2025
Brendan P. O'Grady executed a waiver and release agreement on November 17, 2025.
Rolvedon net sales $38.6M vs $15.0M YoY; large distributor purchases pulled forward two quarters of demand.
Assertio appoints Mark Reisenauer as CEO, replacing Brendan O'Grady
CEO Brendan O'Grady separated effective Oct 27, 2025; entitled to severance under his existing agreement.
Assertio, Hanmi amend ROLVEDON supply agreement; price cut mid-single digits
Mid-single-digit price reduction on ROLVEDON drug substance from Hanmi, fixed through license term.
Assertio Q2 net product sales $28.8M, net loss $16.4M, cash rises to $98.2M
GAAP net loss $16.4M ($0.17 per share) vs $3.7M loss ($0.04) in prior year Q2.
Stockholders approved amendment to certificate of incorporation authorizing board to effect reverse stock split at ratio of 1-for-2 to 1-for-15, to be completed by May 7, 2026.
Net product sales $26.0M vs $31.9M YoY; GAAP net loss $13.5M ($0.14 loss per share) vs $4.5M loss.
Assertio Reports Fourth Quarter and Full Year 2024 Financial Results
Q4 2024 net product sales were $29.6 million, up from $28.7 million in Q3 2024.
Assertio receives Nasdaq deficiency notice for bid price below $1.00 per share
Stock closed below $1 for 32 consecutive business days; Nasdaq issued notice on Jan. 22, 2025.
Assertio appoints Schwichtenberg as CTO, Pietryga as CCO, Reisenauer to board
Paul Schwichtenberg (formerly CCO, CFO) named Chief Transformation Officer effective Dec 16, 2024, focusing on growth and new revenue strategies.
Assertio Q3 net sales $28.7M, adj EBITDA $5.3M; board adds Stark, loses Staple/Vacirca
Q3 net product sales $28.7M vs $35.1M YoY; net loss $2.9M vs $279.5M loss (prior year impairment).
Assertio Q2 net product sales $30.7M, GAAP net loss $3.7M; reiterates FY guidance
Net product sales $30.7M vs $40.1M in Q2 2023; GAAP net loss $0.04/share vs income $0.13/share.
Shareholders approved amendment to 2014 Omnibus Incentive Plan, adding 3,390,000 shares for issuance.
Assertio appoints Brendan P. O'Grady as new CEO effective May 29, 2024
Brendan P. O'Grady appointed CEO and director, effective May 29, 2024.
Assertio Q1 net product sales $31.9M; Rolvedon sales grow to $14.5M; guides FY $110-125M
Net product sales of $31.9M in Q1 2024 vs $41.8M in Q1 2023; net loss of $4.5M vs $3.5M loss.
Assertio director Tyree declines reelection over board retirement policy dispute
James L. Tyree, Compensation Committee Chair, will not stand for reelection at 2024 annual meeting.
Assertio regains Nasdaq minimum bid price compliance
Received Nasdaq letter on March 26, 2024 confirming regained compliance.
Assertio files 8-K/A to furnish Q4 2023 earnings call transcript; no new financial data
Amendment filed to furnish transcript of March 11, 2024 earnings call; original 8-K delayed due to vendor technical issues.
Q4 net product sales $32.5M (down 35% YoY); net loss $57.4M vs. income $88.6M in Q4 2022.
Assertio Holdings receives Nasdaq delisting notice for bid price below $1.00
Received Nasdaq notice on Feb 21, 2024, because common stock bid price closed below $1.00 for 30 consecutive business days.
Former CEO Daniel A. Peisert resigns from Assertio Holdings Board
Daniel A. Peisert, former President and CEO, executed a waiver and release on Jan 24, 2024.
Assertio Holdings CEO Daniel Peisert departs; board member Heather Mason named interim CEO
CEO Daniel Peisert separated effective Jan 2, 2024; entitled to severance under management continuity agreement.
Assertio appoints Sravan Emany to Board of Directors, effective Nov 14.
Board expanded from 6 to 7 members; Emany fills new vacancy created by increase.
Assertio posts Q3 net loss of $279.5M; names Ajay Patel CFO, Schwichtenberg to commercial role
Q3 GAAP net loss $279.5M ($3.42 EPS); adjusted EPS $0.01; includes $238.8M impairment charge.
Assertio amends 8-K to eliminate requirement to file Spectrum acquisition financials
Amendment removes earlier commitment to file financial statements and pro forma for Spectrum acquisition.
Assertio Q2 sales up 13% to $40.1M; closes Spectrum buy; withdraws guidance on generic Indocin
Net product sales $40.1M (+13% YoY); GAAP net income $8.5M ($0.13 EPS), adjusted EPS $0.19 vs $0.28 YoY.
Assertio closes acquisition of Spectrum Pharmaceuticals; expects accretion in 2024
Acquisition of Spectrum closed July 31, 2023; each Spectrum share converted into 0.1783 Assertio shares plus one CVR worth up to $0.20.
Assertio lowers stockholder meeting quorum to one-third of voting power
Board adopted amendment reducing quorum from majority to one-third of outstanding voting power.
Shareholders approve 4.15M share increase to 2014 Plan; fail to pass subsidiary charter amendment
Approved 4,150,000 share increase to 2014 Omnibus Incentive Plan (Proposal 2).
Assertio Q1 sales +18% to $41.8M; raises FY2023 outlook; plans Spectrum acquisition in Q3
Q1 net product sales $41.8M, up 18% YoY; GAAP net loss of $3.5M vs net income of $9.1M a year ago.
Assertio to acquire Spectrum Pharma in all-stock deal with CVRs, 0.1783 exchange ratio
Each Spectrum share converts into 0.1783 Assertio shares plus one contingent value right (CVR).
Assertio to acquire Spectrum in all-stock plus contingent value rights deal
Assertio will acquire all outstanding Spectrum shares via all-stock and contingent value rights transaction.
Assertio Holdings confirms no deposits or accounts at Silicon Valley Bank
Company has zero deposits, funds, or securities at SVB; no active accounts.
Assertio Q4 net product sales $49.9M (+55% YoY); net income $88.6M; guides 2023 revenue $150-160M
Net product sales Q4 $49.9M (+55% YoY); full year $155.1M (+42% YoY).
$30M principal of 6.50% Convertible Senior Notes due 2027 exchanged for $10.5M cash and ~7M shares.
On November 7, 2024, Peter Staple notified the Board of Directors (the “Board”) of the Company of his intent to retire as a member of the Board, effective November 7, 2024
On November 7, 2024, Jeffrey Vacirca also notified the Board of the Company of his intent to retire as a member of the Board and its committees, effective as of the Effective Date.
On November 7, 2024, the Board appointed David Stark to the Board, effective as of the Effective Date.
Heather L. Mason, who has served as Interim Chief Executive Officer since January 2024, will transition back to her role as independent director.
appointed Brendan P. O’Grady to serve as the Company’s Chief Executive Officer (and principal executive officer) and as a director.
On March 27, 2024, James L. Tyree, Chairman of the Compensation Committee of the Board of Directors (the “Board”) of Assertio Holdings, Inc. (the “Company”), informed the Board at an informal meeting that he declined to stand for reelection at the 2024 Annual Meeting of Stockholders.
the Board of Directors (the “Board”) of the Company appointed Sigurd Kirk to the Board, effective April 3, 2024
Pursuant to and in connection with his execution of the Waiver and Release Agreement, Mr. Peisert resigned as a member of the Board of Directors of the Company, effective immediately.
the Board of Directors of the Company (the “Board”) appointed Heather L. Mason, currently a member of the Board, to serve as the Company’s Interim Chief Executive Officer
Effective as of January 2, 2024, Daniel A. Peisert, President and Chief Executive Officer and a director of Assertio Holdings, Inc. (the “Company”) separated from service as President and Chief Executive Officer of the Company.
appointed Sravan Emany to the Board, to fill the vacancy created by the increase in the number of directors.
the appointment of Ajay Patel as Chief Financial Officer in addition to his current role as Senior Vice President and Chief Accounting Officer
Max materiality 1.00 · Median 0.65 · Most common event m_and_a